Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | DBH | P09172 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 7/20 | 0.48 |
| ▸ | ALPL | P05186 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9768178 | 0.85 | KDM4E (0.53) | KDM4EGAADBHRECQLALPG | |
| SCHEMBL29391092 | 0.85 | KDM4E (0.53) | KDM4EGAADBHRECQLALPG | |
| Hydrochloric Acid SCHEMBL11290306 | 0.84 | KDM4E (0.51) | KDM4EGAADBHRECQLALPG | |
| SCHEMBL10071964 | 0.81 | SIGMAR1 (0.53) | ALPGALPLPOLBDPP4 | |
| SCHEMBL4983444 | 0.79 | DPP4 (0.64) | KDM4EGAACA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL4987086 | 0.78 | DPP4 (0.62) | KDM4EGAACA12CA1CA2 | |
| SCHEMBL6046293 | 0.77 | ALPG (0.52) | KDM4EGAADBHRECQLALPG | |
| Adrenalone SCHEMBL123124 | 0.76 | ALPG (0.55) | KDM4EGAADBHRECQLALPG | |
| Adrenalone SCHEMBL29550997 | 0.76 | ALPG (0.55) | KDM4EGAADBHRECQLALPG | |
| SCHEMBL9768252 | 0.76 | KDM4E (0.50) | KDM4EGAADBHRECQLALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266817-B2 | Catecholamine derivatives for obesity and neurological disorders | EMORY UNIVERSITY (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010107866-A2 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-5047592-A | Selective hydrogenolysis process | ETHYL CORPORATION (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | KDM4E 2077/4885GAA 294/4885DBH 14/4885 |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | KDM4E 2077/4885GAA 294/4885DBH 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.